Essentially, cereblon and its target proteins can change shape to form a complex with the cereblon, the target, and the ...

Furthermore, the researchers reported that deletion of BCL11A in a conditional mouse model, in either a p53-positive or p53-negative genetic background, abolishes tumour formation and maintenance.

In 2021, research led by Ryan Flynn, MD, Ph.D., and his mentor, Nobel laureate Carolyn Bertozzi, Ph.D., opened a new chapter in biology, characterizing a new kind of player on the cell surface ...

"When we reduced the activity of BCL11A in three samples of human triple-negative breast cancer cells, they lost some characteristics of cancer cells and became less tumorigenic when tested in ...

Researchers have set their sights on a new therapeutic target for an aggressive form of breast cancer with limited treatment options. Through a comprehensive and cutting-edge genomic screening ...

A strategy that analyzes the structural properties of RNA could help identify regions that are promising targets for antiviral drugs.

BCL11A: Evidence for neuroprotective effect Researchers at the University of Bonn investigate the role of the transcription factor for dopamine-producing neurons Peer-Reviewed Publication ...

Researchers from the UK have found that overactivity in a gene called BCL11A may lead to the development and progression of triple-negative breast cancer.

One of Monte Rosa's main differentiating factors is its proprietary QuEEN platform to design new molecular glue degraders. Read why GLUE stock is a Buy.

BCL11A: Evidence for neuroprotective effect Date: September 14, 2021 Source: University of Bonn Summary: The neurotransmitter dopamine influences the activity of a wide variety of brain areas. A ...

Researchers at VCU Massey Cancer Center have set their sights on a new therapeutic target for an aggressive form of breast cancer with limited treatment options.